Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Verisign, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Verisign, Inc. trades at $302.35 (market cap $27.25B). The key difference: Verisign, Inc. is far larger — about 27.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Verisign, Inc. pays a 1.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Verisign, Inc. for 124 Days on average.
| MRVI | VRSN | |
|---|---|---|
Market Cap | $977.37M | $27.25B |
Volume | 2,742,564 | 709,982 |
Sector | Health | Technology |
52-Week High | $9.00 | $310.00 |
52-Week Low | $2.83 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $1.08B | $28.55B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VeriSign (VRSN) trades at $301.76, down 0.31% with mixed earnings performance. The stock shows bullish technical signals with strong institutional buying and a $348 consensus price target. Recent Q2 2026 results showed 6% revenue growth and 7.7% EPS increase, though Q3 2026 earnings are pending. The company maintains exceptional profitability with 49.77% net margins and robust cash flow generation.
Outlook remains positive with AI-driven domain growth and pending price increases supporting double-digit profit potential. Key risks include antitrust litigation and high valuation multiples. Analyst consensus leans bullish with 60% buy ratings, though insider selling and elevated P/E of 32.73 warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
